Atlas Venture Fund XI, L.P.

Insider Reports History

Location
Cambridge, MA
Signature
Atlas Venture Fund XI, L.P., By: Atlas Venture Associates XI, L.P., its general partner, by Atlas Venture Associates XI, LLC, its general partner, By: /s/ Ommer Chohan, Chief Financial Officer
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Atlas Venture Fund XI, L.P.:

Company Role Class Num Shares Value Price $ Report Date Ownership
Dyne Therapeutics, Inc. 10%+ Owner Common Stock 5,698,091 $143,876,798 $25.25 28 Feb 2024 Direct
Third Harmonic Bio, Inc. 10%+ Owner Common Stock 9,798,075 $140,112,473 $14.30 01 Nov 2024 Direct
Day One Biopharmaceuticals, Inc. 10%+ Owner Common Stock 6,008,534 $70,239,762 $11.69 12 Dec 2022 Direct
Dyne Therapeutics, Inc. 10%+ Owner Common Stock 864,487 $21,828,297 $25.25 28 Feb 2024 Indirect
Ikena Oncology, Inc. 10%+ Owner Common Stock 1,241,935 $6,669,191 $5.37 14 Dec 2021 Direct
Ikena Oncology, Inc. 10%+ Owner Common Stock 874,634 $4,696,785 $5.37 30 Mar 2021 Indirect
Xilio Therapeutics, Inc. 10%+ Owner Common Stock 2,019,563 $1,292,520 $0.6400 08 Feb 2024 Direct
Xilio Therapeutics, Inc. 10%+ Owner Common Stock 734,546 $470,109 $0.6400 08 Feb 2024 Indirect
Sionna Therapeutics, Inc. 10%+ Owner Common Stock 2,886,293 10 Feb 2025 Direct
Sionna Therapeutics, Inc. 10%+ Owner Common Stock 807,727 10 Feb 2025 By Atlas Venture Opportunity Fund II, L.P.
Sionna Therapeutics, Inc. 10%+ Owner Series A convertible preferred stock 0 10 Feb 2025 Direct
Sionna Therapeutics, Inc. 10%+ Owner Series B convertible preferred stock 0 10 Feb 2025 Direct
Sionna Therapeutics, Inc. 10%+ Owner Series C convertible preferred stock 0 10 Feb 2025 By Atlas Venture Opportunity Fund II, L.P.
Sionna Therapeutics, Inc. 10%+ Owner Series C convertible preferred stock 0 10 Feb 2025 Direct
Sionna Therapeutics, Inc. 10%+ Owner Series Seed convertible preferred stock 0 10 Feb 2025 Direct

Insider Reports Filed by Atlas Venture Fund XI, L.P.

Symbol Company Period Transactions Value $ Form Type Role Filing Time
SION Sionna Therapeutics, Inc. 10 Feb 2025 8 +$1,080,000 4 10%+ Owner 10 Feb 2025, 16:05
SION Sionna Therapeutics, Inc. 06 Feb 2025 0 $0 3 10%+ Owner 06 Feb 2025, 21:12
THRD Third Harmonic Bio, Inc. 01 Nov 2024 1 $0 4 10%+ Owner 05 Nov 2024, 16:15
DYN Dyne Therapeutics, Inc. 26 Feb 2024 18 -$19,626,903 4 10%+ Owner 28 Feb 2024, 19:13
DYN Dyne Therapeutics, Inc. 21 Feb 2024 6 -$11,339,780 4 10%+ Owner 23 Feb 2024, 18:58
DYN Dyne Therapeutics, Inc. 15 Feb 2024 5 -$11,867,292 4 10%+ Owner 20 Feb 2024, 18:35
XLO Xilio Therapeutics, Inc. 08 Feb 2024 2 -$640 4 10%+ Owner 09 Feb 2024, 16:33
XLO Xilio Therapeutics, Inc. 11 Jan 2024 4 -$3,600 4 10%+ Owner 16 Jan 2024, 18:16
DAWN Day One Biopharmaceuticals, Inc. 12 Dec 2022 1 $0 4 10%+ Owner 14 Dec 2022, 15:54
DAWN Day One Biopharmaceuticals, Inc. 19 Sep 2022 1 $0 4 10%+ Owner 21 Sep 2022, 16:58
THRD Third Harmonic Bio, Inc. 19 Sep 2022 7 +$5,100,000 4 10%+ Owner 19 Sep 2022, 16:51
THRD Third Harmonic Bio, Inc. 14 Sep 2022 0 $0 3 10%+ Owner 14 Sep 2022, 18:03
DAWN Day One Biopharmaceuticals, Inc. 24 Nov 2021 1 $0 4 10%+ Owner 29 Nov 2021, 16:30
XLO Xilio Therapeutics, Inc. 26 Oct 2021 7 +$3,000,000 4 10%+ Owner 26 Oct 2021, 17:01
XLO Xilio Therapeutics, Inc. 21 Oct 2021 0 $0 3 10%+ Owner 21 Oct 2021, 20:48
DYN Dyne Therapeutics, Inc. 13 Jul 2021 1 $0 4 10%+ Owner 15 Jul 2021, 16:33
DAWN Day One Biopharmaceuticals, Inc. 26 May 2021 0 $0 3 10%+ Owner 26 May 2021, 21:55
IKNA Ikena Oncology, Inc. 30 Mar 2021 4 +$1,614,428 4 10%+ Owner 14 Dec 2021, 19:27
DAWN Day One Biopharmaceuticals, Inc. 01 Feb 2021 7 +$8,000,000 4 10%+ Owner 02 Jun 2021, 18:40